Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777084
Status:
RECRUITING
Last Update Posted:
2023-12-27
First Post:
2021-02-27
Brief Title:
The Efficacy and Safety of the Bispecific Anti-PD-1PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Organization Data
Organization:
Hunan Province Tumor Hospital
Class:
OTHER
Study ID:
LIVE
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hunan Province Tumor Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Yongchang Zhang
Responsible Party Title:
Professor Deputy Director of Thoracic Oncology Department
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Hunan Province Tumor Hospital
Old Name:
None
Old Organization:
None